The Indian Journal of Pediatrics

, Volume 86, Issue 3, pp 229–232 | Cite as

Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children

  • C. K. IndumathiEmail author
  • Aruna Sethuraman
  • Saurav Jain
  • Savita Krishnamurthy
Original Article



To compare the incidence of anti tuberculosis drug-induced hepatotoxicity (ATDH) with those on old vs. revised WHO doses in human immunodeficiency virus (HIV) negative children. The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT).


Children attending pediatric outpatient / admitted in wards, on ATT/ IPT between January 2007 and December 2017 (11 y) were included. Children were divided into Group 1 (treated based on old doses, from January 2007 to December 2011) and Group 2 (treated based on revised doses from January 2012 to December 2017). Children with multi drug resistant tuberculosis (MDRTB) and pre-existing liver disease were excluded.


A total of 515 children were enrolled. Twelve children developed ATDH with an overall incidence of 2.3%. Five out of 260 (1.9%) developed hepatitis with old doses vs. 7 of the 255 (2.7%) with revised doses; this difference was not statistically significant. When calculated only for active TB (excluding children on IPT), overall incidence of hepatitis was 2.7%. Comparison between group 1 (2.04%) and group 2 (3.5%) was again not statistically significant. Ten out of 12 children who developed hepatitis were restarted on ATT without recurrence. No child on IPT developed hepatitis. There was no mortality.


Revised WHO dosing does not increase incidence of hepatitis compared to old dosing in HIV negative children. Overall incidence was 2.3%. Hepatitis did not occur with IPT.


Antituberculosis Drug induced hepatotoxicity Revised doses 



ICK was responsible for study concept, study design and writing the paper. All authors were involved in clinical care, data collection and revision of the manuscript.

Compliance with Ethical Standards

Conflict of Interest


Source of Funding



  1. 1.
    Tostmann A, Boeree MJ, Aarnoutse RE, De Lange W, Van Der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202.CrossRefGoogle Scholar
  2. 2.
    Devarbhavi H. Antituberculous drug-induced liver injury: current perspective. Trop Gastroenterol. 2011;32:167–74.Google Scholar
  3. 3.
    Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:51–64.CrossRefGoogle Scholar
  4. 4.
    Devrim İ, Olukman Ö, Can D, Dizdarer C. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Chest. 2010;137:737–8.CrossRefGoogle Scholar
  5. 5.
    Kumar A, Sood V, Khanna R, et al. Clinical spectrum and outcome of pediatric drug induced liver injury. Indian J Pediatr. 2017;85:676–8.CrossRefGoogle Scholar
  6. 6.
    World Health Organization. Rapid Advice: Treatment of Tuberculosis in Children. 2010; Available at: Accessed 19 July 2018.
  7. 7.
    Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50:S184–94.CrossRefGoogle Scholar
  8. 8.
    Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis. 2015;15:126.CrossRefGoogle Scholar
  9. 9.
    Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther. 2002;72:220–6.CrossRefGoogle Scholar
  10. 10.
    Mansukhani S, Shah I. Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy. Ann Hepatol. 2012;11:96–9.Google Scholar
  11. 11.
    Aishatu G, Rasheedah I, Wahab J, Sheni M, Damilola O, Adeniyi O. Hepatotoxicity due to antituberculosis therapy among paediatric patients seen at the University of Ilorin Teaching Hospital, north Central Nigeria. Ethiop J Health Sci. 2017;27:115–20.CrossRefGoogle Scholar
  12. 12.
    Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52.CrossRefGoogle Scholar
  13. 13.
    Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014–8.CrossRefGoogle Scholar
  14. 14.
    Indumathi C, Kumar G, Sethuraman A, Iyengar A. Evaluation of efficacy and adherence to INH preventive therapy in children at risk to develop active tuberculosis. Pediatr Infect Dis. 2014;6:21–4.CrossRefGoogle Scholar
  15. 15.
    Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–7.CrossRefGoogle Scholar
  16. 16.
    McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of south African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48:1547–53.CrossRefGoogle Scholar
  17. 17.
    Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res. 2013;7:292–5.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  • C. K. Indumathi
    • 1
    Email author
  • Aruna Sethuraman
    • 1
  • Saurav Jain
    • 1
  • Savita Krishnamurthy
    • 1
  1. 1.Department of PediatricsSt John’s Medical College HospitalBengaluruIndia

Personalised recommendations